Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Investigational Product 1 (IP1) is a dietary supplement formulated as a 25 mL daily dose containing 5 g of collagen, 1.5 g of MSM (Methylsulfonylmethane), and 80 mg of vitamin C. It is being investigated for its beneficial effects on various skin parameters, including dermis density, wrinkles, skin hydration, trans-epidermal water loss (TEWL), dermis thickness, skin texture, and skin elasticity. Collagen is a primary structural protein in the skin, contributing to its strength and elasticity. MSM is often used for its potential anti-inflammatory and antioxidant properties, and its role in supporting connective tissues. Vitamin C is an essential cofactor for collagen synthesis and acts as an antioxidant, protecting skin from oxidative damage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Investigational Product 1.